JFL Life Sciences IPO vs Rhetan TMT IPO

Comparison between JFL Life Sciences IPO and Rhetan TMT IPO.

IPO Details

JFL Life Sciences IPO is a SME Fixed Price IPO proposed to list at NSE SME while Rhetan TMT IPO is a SME Fixed Price proposed to list at BSE SME.

Issue Size and Price

The total issue size of JFL Life Sciences IPO is up to ₹17.25 Cr whereas the issue size of the Rhetan TMT IPO is up to ₹53.09 Cr. The final issue price of JFL Life Sciences IPO is ₹61.00 per share and of Rhetan TMT IPO is ₹70.00 per share.

 JFL Life Sciences IPORhetan TMT IPO
Face Value₹10 per share₹10 per share
Issue Price (Final)₹61.00 per share₹70.00 per share
Discount (Retail)₹0.00 per share₹0.00 per share
Market Lot Size2000 shares2000 shares
Fresh Issue Size28,28,000 shares75,84,000 shares
Fresh Issue Size (Amount)up to ₹17.25 Crup to ₹53.09 Cr
OFS Issue Size0 shares0 shares
OFS Issue Size (Amount)up to ₹0.00 Crup to ₹0.00 Cr
Issue Size Total28,28,000 shares75,84,000 shares
Issue Size Total (Amount)up to ₹17.25 Crup to ₹53.09 Cr

IPO Timetable

JFL Life Sciences IPO opens on Aug 25, 2022, while Rhetan TMT IPO opens on Aug 22, 2022. The closing date of JFL Life Sciences IPO and Rhetan TMT IPO is Aug 30, 2022, and Aug 25, 2022, respectively.

 JFL Life Sciences IPORhetan TMT IPO
Issue OpenAug 25, 2022Aug 22, 2022
Issue CloseAug 30, 2022Aug 25, 2022
Basis Of Allotment (Tentative)Sep 05, 2022Aug 30, 2022
Initiation of Refunds (Tentative)Sep 06, 2022Sep 01, 2022
Credit of Share (Tentative)Sep 07, 2022Sep 02, 2022
Listing date (Tentative)Sep 08, 2022Sep 05, 2022

Financials & KPIs

JFL Life Sciences IPO P/E ratio is 26.52, as compared to Rhetan TMT IPO P/E ratio of 63.64.

 JFL Life Sciences IPORhetan TMT IPO
Financials

Company Financials (Restated)

Period Ended28 Feb 202231 Mar 202131 Mar 202031 Aug 2019
Assets36.6329.0124.3316.15
Total Income25.6332.8730.2031.78
Profit After Tax2.530.540.360.30
NET Worth10.976.875.385.01
Reserves and Surplus2.946.384.954.59
Amount in ₹ Crore

Company Financials (Restated)

Period Ended31 Mar 202231 Mar 202131 Mar 2020
Assets59.0039.8130.47
Total Income67.0352.1320.08
Profit After Tax2.350.13-0.58
NET Worth23.137.840.30
Reserves and Surplus10.46-2.98-3.12
Amount in ₹ Crore
Promoter Shareholding (Pre-Issue)92.52%99.62%
Promoter Shareholding (Post-Issue)67.47%62.12%
P/E Ratio26.5263.64
Market Cap₹67.09 Cr.₹148.75 Cr.
ROE15
ROCE8
Debt/Equity1.15
EPS₹0.89₹2.00
RoNW7.8910.14

Shares Offered

In the JFL Life Sciences IPO Retail Individual Investors (RII) are offered 14,14,000 shares while in Rhetan TMT IPO retail investors are offered 14,14,000 shares. Qualified Institutional Buyers (QIB) are offered in JFL Life Sciences IPO and in Rhetan TMT IPO.

 JFL Life Sciences IPORhetan TMT IPO
Market Maker Reservation1,50,000 shares4,16,000 shares
NII14,14,000 shares37,92,000 shares
RII14,14,000 shares37,92,000 shares
Total28,28,000 shares75,84,000 shares

Bids Received (Subscription)

JFL Life Sciences IPO subscribed 8.93x in total, whereas Rhetan TMT IPO subscribed 1.47x.

 JFL Life Sciences IPORhetan TMT IPO
NII (times)6.19x2.18x
RII (times)11.66x0.76x
Total (times)8.93x1.47x

Compare with others

Compare: